Immunosuppression
View More View Less
  • 1 Division of Nephrology and Transplantation, Maine Medical Center, and Tufts University School of Medicine, Portland, Maine
  • 2 Division of Renal Diseases and Hypertension, Transplant Center, University of Colorado Denver, Aurora, Colorado
  • 1

    Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Robinson A, : OPTN/SRTR 2016 Annual Data Report: Kidney. Am J Transplant 18[Suppl 1]: 18113, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Sampaio MS, Chopra B, Sureshkumar KK: Depleting antibody induction and kidney transplant outcomes: A paired kidney analysis. Transplantation 101: 25272535, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Nafar M, Dalili N, Poor-Reza-Gholi F, Ahmadpoor P, Samadian F, Samavat S: The appropriate dose of thymoglobulin induction therapy in kidney transplantation. Clin Transplant 31: 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Koyawala N, Silber JH, Rosenbaum PR, Wang W, Hill AS, Reiter JG, : Comparing outcomes between antibody induction therapies in kidney transplantation. J Am Soc Nephrol 28: 21882200, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Cremaschi L, von Versen R, Benzing T, Wiesener M, Zink N, Milkovich G, : Induction therapy with rabbit antithymocyte globulin versus basiliximab after kidney transplantation: A health economic analysis from a German perspective. Transpl Int 30: 10111019, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Sandal S, Bae S, McAdams-DeMarco M, Massie AB, Lentine KL, Cantarovich M, : Induction immunosuppression agents as risk factors for incident cardiovascular events and mortality after kidney transplantation. Am J Transplant 19: 11501159, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Ravindra KV, Sanoff S, Vikraman D, Zaaroura A, Nanavati A, Sudan D, : Lymphocyte depletion and risk of acute rejection in renal transplant recipients at increased risk for delayed graft function. Am J Transplant 19: 781789, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Hellemans R, Bosmans JL, Abramowicz D: Induction therapy for kidney transplant recipients: Do we still need anti-IL2 receptor monoclonal antibodies? Am J Transplant 17: 2227, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Mincham CM, Wong G, Teixeira-Pinto A, Kennedy S, Alexander S, Larkins N, : Induction therapy, rejection, and graft outcomes in pediatric and adolescent kidney transplant recipients. Transplantation 101: 21462151, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Dharnidharka VR, Naik AS, Axelrod DA, Schnitzler MA, Zhang Z, Bae S, : Center practice drives variation in choice of US kidney transplant induction therapy: A retrospective analysis of contemporary practice. Transpl Int 31: 198211, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Banham GD, Flint SM, Torpey N, Lyons PA, Shanahan DN, Gibson A, : Belimumab in kidney transplantation: An experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet 391: 26192630, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Michielsen LA, van Zuilen AD, Verhaar MC, Wisse BW, Kamburova EG, Joosten I, : Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients [published online ahead of print Dec 15, 2018 ]. Nephrol Dial Transplant doi: . PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Stegall MD, Cornell LD, Park WD, Smith BH, Cosio FG: Renal allograft histology at 10 years after transplantation in the tacrolimus era: Evidence of pervasive chronic injury. Am J Transplant 18: 180188, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Serrano OK, Kandaswamy R, Gillingham K, Chinnakotla S, Dunn TB, Finger E, : Rapid discontinuation of prednisone in kidney transplant recipients: 15-year outcomes from the University of Minnesota. Transplantation 101: 25902598, 2017 PubMed

    • Search Google Scholar
    • Export Citation
  • 15.

    Taber DJ, Hunt KJ, Gebregziabher M, Srinivas T, Chavin KD, Baliga PK, : A comparative effectiveness analysis of early steroid withdrawal in black kidney transplant recipients. Clin J Am Soc Nephrol 12: 131139, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Tremblay S, Nigro V, Weinberg J, Woodle ES, Alloway RR: A steady-state head-to-head pharmacokinetic comparison of all fk-506 (tacrolimus) formulations (ASTCOFF): An open-label, prospective, randomized, two-arm, three-period crossover study. Am J Transplant 17: 432442, 2017https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27340950&dopt=Abstract

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Trofe-Clark J, Brennan DC, West-Thielke P, Milone MC, Lim MA, Neubauer R, : Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American kidney transplant recipients. Am J Kidney Dis 71: 315326, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Glander P, Waiser J, Kasbohm S, Friedersdorff F, Peters R, Rudolph B, : Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation. Clin Transplant 32: e13311, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Lehner LJ, Reinke P, Hörstrup JH, Rath T, Suwelack B, Krämer BK, : Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study. Clin Transplant 32: e13142, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Størset E, Gustavsen MT, : High tacrolimus clearance is a risk factor for acute rejection in the early phase after renal transplantation. Transplantation 101: e273e279, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Gatault P, Kamar N, Büchler M, Colosio C, Bertrand D, Durrbach A, : Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor-specific antibodies: A randomized study. Am J Transplant 17: 13701379, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22.

    Leino AD, King EC, Jiang W, Vinks AA, Klawitter J, Christians U, : Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. Am J Transplant 19: 14101420, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Taber DJ, Su Z, Fleming JN, McGillicuddy JW, Posadas-Salas MA, Treiber FA, : Tacrolimus trough concentration variability and disparities in African American kidney transplantation. Transplantation 101: 29312938, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24

    Asempa TE, Rebellato LM, Hudson S, Briley K, Maldonado AQ: Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients. Clin Transplant 32: 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 25

    Seibert SR, Schladt DP, Wu B, Guan W, Dorr C, Remmel RP, : Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. Clin Transplant 32: e13424, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 26.

    Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, ; TRANSFORM Investigators: Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol 29: 19791991, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27.

    Qazi Y, Shaffer D, Kaplan B, Kim DY, Luan FL, Peddi VR, : Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data. Am J Transplant 17: 13581369, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Shihab F, Qazi Y, Mulgaonkar S, McCague K, Patel D, Peddi VR, : Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of tacrolimus. Am J Transplant 17: 23632371, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Sommerer C, Duerr M, Witzke O, Lehner F, Arns W, Kliem V, ; HERAKLES Study Group: Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. Am J Transplant 18: 29652976, 2018https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29722128&dopt=Abstract

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Budde K, Zeier M, Witzke O, Arns W, Lehner F, Guba M, ; HERAKLES Study Group: Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: A multicentre, randomized trial. Nephrol Dial Transplant 32: 10601070, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Rummo OO, Carmellini M, Rostaing L, Oberbauer R, Christiaans MH, Mousson C, ; ADHERE study investigators: ADHERE: Randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus. Transpl Int 30: 8395, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32.

    de Fijter JW, Holdaas H, Øyen O, Sanders JS, Sundar S, Bemelman FJ, ; ELEVATE Study Group: Early conversion from calcineurin inhibitor- to everolimus-based therapy following kidney transplantation: Results of the randomized ELEVATE trial. Am J Transplant 17: 18531867, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33.

    Bemelman FJ, de Fijter JW, Kers J, Meyer C, Peters-Sengers H, de Maar EF, : Early conversion to prednisolone/everolimus as an alternative weaning regimen associates with beneficial renal transplant histology and function: The randomized-controlled MECANO trial. Am J Transplant 17: 10201030, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34.

    Group CSC; 3C Study Collaborative Group: Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study): Results of a randomized controlled clinical trial. Am J Transplant 18: 14241434, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 35.

    Florman S, Becker T, Bresnahan B, Chevaile-Ramos A, Carvalho D, Grannas G, : Efficacy and safety outcomes of extended criteria donor kidneys by subtype: Subgroup analysis of BENEFIT-EXT at 7 years after transplant. Am J Transplant 17: 180190, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36

    Florman S, Vincenti F, Durrbach A, Abouljoud M, Bresnahan B, Garcia VD, : Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT. Clin Transplant 32: e13225, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 37.

    Adams AB, Goldstein J, Garrett C, Zhang R, Patzer RE, Newell KA, : Belatacept combined with transient calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function. Am J Transplant 17: 29222936, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 38.

    de Graav GN, Baan CC, Clahsen-van Groningen MC, Kraaijeveld R, Dieterich M, Verschoor W, : A randomized controlled clinical trial comparing belatacept with tacrolimus after de novo kidney transplantation. Transplantation 101: 25712581, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39.

    Leibler C, Matignon M, Moktefi A, Samson C, Zarour A, Malard S, : Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR). Am J Transplant 19: 894906, 2019 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40.

    Mathews DV, Wakwe WC, Kim SC, Lowe MC, Breeden C, Roberts ME, : Belatacept-resistant rejection is associated with CD28+ memory CD8 T cells. Am J Transplant 17: 22852299, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41.

    Cortes-Cerisuelo M, Laurie SJ, Mathews DV, Winterberg PD, Larsen CP, Adams AB, : Increased pretransplant frequency of CD28+ CD4+ TEM predicts belatacept-resistant rejection in human renal transplant recipients. Am J Transplant 17: 23502362, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42.

    Vincenti F, Blancho G, Durrbach A, Grannas G, Grinyó J, Meier-Kriesche HU, : Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly. Am J Transplant 17: 32193227, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 43.

    Grinyó JM, Del Carmen Rial M, Alberu J, Steinberg SM, Manfro RC, Nainan G, : Safety and efficacy outcomes 3 years after switching to belatacept from a calcineurin inhibitor in kidney transplant recipients: Results from a phase 2 randomized trial. Am J Kidney Dis 69: 587594, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 44.

    Darres A, Ulloa C, Brakemeier S, Garrouste C, Bestard O, Del Bello A, : Conversion to belatacept in maintenance kidney transplant patients: A retrospective multicenter European study. Transplantation 102: 15451552, 2018 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45.

    Abdelwahab Elhamahmi D, Heilman RL, Smith B, Huskey J, Khamash H, Kaplan B: Early conversion to belatacept in kidney transplant recipients with low glomerular filtration rate. Transplantation 102: 478483, 2018 PubMed

    • Search Google Scholar
    • Export Citation
  • 46.

    Bertrand D, Cheddani L, Etienne I, François A, Hanoy M, Laurent C, : Belatacept rescue therapy in kidney transplant recipients with vascular lesions: A case control study. Am J Transplant 17: 29372944, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 47.

    Lerch C, Kanzelmeyer NK, Ahlenstiel-Grunow T, Froede K, Kreuzer M, Drube J, : Belatacept after kidney transplantation in adolescents: A retrospective study. Transpl Int 30: 494501, 2017 PubMed

    • Crossref
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 839 839 6
Full Text Views 862 861 54
PDF Downloads 512 512 24